Kyowa Kirin Co., Ltd.
PharmaTokyo, Japan, Japan · Est. 1949 · 3,700 employees
Kyowa Kirin is a Japanese pharmaceutical company focused on developing and commercializing innovative medicines in oncology, immunology, nephrology, and other therapeutic areas.
17
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
9
Indications↗
Distinct diseases across all programs
157
Clinical Trials↗
All sponsored trials (all statuses)
2
Orange Book Patents
Across 1 drug with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
17 drugs in development
Phase 31
Phase 23
Phase 113
By Therapeutic Area
top 4
Oncology
212%
Ophthalmology
16%
Cardiovascular
16%
Immunology
16%
R&D Momentum
46/100
Pipeline Velocity
6/100
Trial Completion Rate
89/100
Pipeline Concentration
52/100
Pipeline Freshness
75/100
Strategic Signals
- ↗Early-stage heavy pipeline may seek late-stage partners
- ↗Active in Ophthalmology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Earlier
Aug 8, 2026TrialA Phase 1/2, Multicenter, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KK2430 in Participants With Hematologic Neoplasms
Aug 4, 20268-K8-K
Aug 3, 20268-KFORM 8-K
Jul 2, 2026TrialA Phase 1, Placebo-Controlled, Double-Blind, Randomized, Single and Multiple Ascending-Dose Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension
Jul 2, 2026TrialA Phase I, Multicenter, Non-controlled, Open-label, Non-randomized, Dose-escalation Study of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Other Hematologic Malignancies.
May 2, 2025TrialAssessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance
Dec 1, 2024TrialEvaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia（AOBA Study）
4 more events
Oct 9, 2024TrialA First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia
Jan 31, 2024TrialStudy to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
Jan 9, 2024TrialStudy to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
Nov 1, 2023TrialA Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors
Details
Company Info
Company Overview
$9.5B
Mkt Cap
$2.2B
Revenue
—
Cash
CEOYoshihiko Hatanaka
Founded1949
Employees3,700
HQTokyo, Japan, Japan
Websitekyowakirin.com/
LinkedInCompany Page
Therapeutic Focus
oncologyimmunologynephrologyhematology
Recent SEC Filings
8-KAug 4, 2026
8-K
8-KAug 3, 2026
FORM 8-K
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cardiovascular
Cardiovascular
Essential Hypertension
KK3910Phase 1
Oncology
Ophthalmology
Unknown / Other
Achondroplasia
KK8398Phase 3
Relapsed or Refractory
KK2845_1Phase 1
KK2845_2Phase 1
KK2845_3Phase 1
KK2845_4Phase 1
KK2845_5Phase 1
KK2845_6Phase 1
KK2845_alternative_1Phase 1
KK2845_alternative_2Phase 1
Showing 15 of 18 programs
Regulatory
Regulatory Timeline
19971 event
FDAMay 29
Fareston — FARESTON
Application NDA020497 (NDA)
20182 events
FDAAug 8
POTELIGEO — POTELIGEO
Application BLA761051 (BLA)
FDAApr 17
CRYSVITA — CRYSVITA
Application BLA761068 (BLA)
20192 events
FDAAug 27
Nourianz — NOURIANZ
Application NDA022075 (NDA)
FDAAug 27
Nourianz — NOURIANZ
Application NDA022075
20262 events
SECAug 4
8-K
Accession: 0000277135-26-000076
SECAug 3
FORM 8-K
Accession: 0001104659-26-089478
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)